{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/647732f050150f001123b38e/6a5b91804d4b991ebe671da0?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"ESCMID og vårmøtet 2026 - en liten (stor) reportasje","description":"<p>Ingrid, Jørgen og Nikolai oppsummerer etter beste evne årets ESCMID (en av verdens største infeksjonsmedisinske konferanser) og vårmøtet (kanskje en av verdens minste infeksjonskonferanser) i denne reporasje-baserte episoden av Pestpodden.</p><p><br></p><p><strong><u>Referanser:</u></strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;White NM, et al. <strong>Effectiveness of oral care for the prevention of non-ventilator hospital-acquired pneumonia (HAPPEN): a multicentre, stepped-wedge, cluster-randomised trial in Australia.</strong> Lancet Infect Dis. 2026.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;Israelsen SB, et al. <strong>Short-course antibiotic therapy of 5 days in community-acquired pneumonia (CAP5): study protocol for a randomised controlled trial.</strong> BMJ Open. 2023;13:e069013. doi: 10.1136/bmjopen-2022-069013.&nbsp;&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;Chanderraj R, et al.<strong> Mortality of Patients With Sepsis Administered Piperacillin-Tazobactam vs Cefepime. </strong>JAMA Intern Med. 2024;184(7):769-77.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;Azevedo LCP, et al. <strong>Using the 2026 Surviving Sepsis Campaign Guidelines in Practice.</strong> Crit Care Sci. 2026;38:e20260036.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;Doumat G, et al. <strong>Short Versus Longer Antibiotic Duration for Community-Acquired Pneumonia : A Multicenter Target Trial Emulation. </strong>Ann Intern Med. 2026;179(5):629-36.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;Overdevest AG, et al. <strong>Antibiotic treatment for 1 day versus 4–7 days in patients with acute cholangitis after adequate endoscopic biliary drainage (COBRA): study protocol for a randomized controlled trial.</strong> <em>Trials</em>. 2026. doi: <strong>10.1186/s13063-026-09524-7</strong>. PubMed: PMID <strong>41689066</strong>.&nbsp;</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;Turner NA, et al. <strong>Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial.</strong> JAMA. 2025.</p><p>8.&nbsp;&nbsp;&nbsp;&nbsp;Kristensen LH, et al. <strong>Diagnostic accuracy of dipsticks for urinary tract infections in acutely hospitalised patients: a prospective population-based observational cohort study. </strong>BMJ Evid Based Med. 2025;30(1):36-44.</p><p>9.&nbsp;&nbsp;&nbsp;&nbsp;Giamarellos-Bourboulis EJ, et al. <strong>Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial. </strong>JAMA. 2026;335(9):775-86.</p><p><br></p>","author_name":"Helse Bergen"}